法舒地尔治疗缺血性卒中的多中心SPAN试验
SPAN网络在短暂性局灶性脑缺血啮齿类模型中测试法舒地尔(10 mg/kg腹腔注射,再灌注前5分钟开始,每12小时一次共6次)。活性治疗组(n=345)与溶媒组(n=344)比较,法舒地尔改善小鼠主要终点(概率指数0.57,P=0.022),在衰老鼠和缺血发生于活跃昼夜阶段时效应更强;对自发性高血压大鼠无获益。
要点
- 法舒地尔改善小鼠第28天改良角落测试主要终点(概率指数0.57,P=0.022)。
- 效应在衰老鼠及缺血发生于活跃昼夜阶段时似乎更强。
- 法舒地尔对自发性高血压大鼠未显示任何获益。
核心结论
- 法舒地尔显示出有利的治疗特征,支持Rho相关激酶抑制剂在缺血性卒中的未来转化开发。
研究设计与样本
- SPAN是一项确证性多中心试验网络,在短暂性局灶性缺血性卒中啮齿类模型中测试脑保护干预。
- 本报告为SPAN试验中法舒地尔的预设亚研究,主要终点为第28天改良角落测试表现,对小鼠和自发性高血压大鼠分别分析,采用改良意向治疗队列。
- 法舒地尔10 mg/kg腹腔注射,再灌注前5分钟开始,每12小时一次共6次,用于60分钟血管内线栓大脑中动脉闭塞模型。
- 活性治疗组n=345,与合并的腹腔注射和静脉注射溶媒组n=344比较;除健康年轻小鼠外,纳入衰老小鼠(16±1月龄)、饮食诱导肥胖小鼠和自发性高血压大鼠。
主要发现
- 法舒地尔改善小鼠主要结局终点(概率指数点估计0.57;P=0.022)。
- 效应在衰老小鼠及缺血于活跃昼夜阶段诱导时似乎更强。
- 法舒地尔在自发性高血压大鼠中未显示任何获益。
- 使用符合方案人群和插补的替代分析通常得出相似结论。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The SPAN (Stroke Preclinical Assessment Network) is a confirmatory multicenter trial network to test cerebroprotective interventions in experimental acute stroke. In a first-of-its-kind trial, SPAN tested 6 interventions in a rodent model of transient focal ischemic stroke. Here, we report the efficacy of fasudil, an isoform-nonselective rho-associated kinase inhibitor, on primary and secondary outcomes in the SPAN trial. METHODS: Fasudil was administered at 10 mg/kg intraperitoneally every 12 hours for 6 doses starting 5 minutes before reperfusion in a 60-minute endovascular filament middle cerebral artery occlusion model. The active treatment arm (n=345) was compared with the pooled intraperitoneal and intravenous vehicle arms (n=344). In addition to healthy young mice, the trial included aging mice (16±1 months), diet-induced obese mice, and spontaneously hypertensive rats. The a priori fasudil substudy design stipulated the modified corner test performance on day 28 as the primary end point and separate analyses for mice and spontaneously hypertensive rats using the modified intention-to-treat cohort. RESULTS: Fasudil improved the primary outcome end point in mice (probabilistic index point estimate, 0.57; P=0.022). The effect appeared stronger in aging mice and when ischemia was induced during the active circadian stage. Fasudil did not show any benefit in the spontaneously hypertensive rats. Alternative analyses using the per-protocol population and imputation generally yielded similar conclusions. CONCLUSIONS: Our results reveal a favorable therapeutic profile for fasudil, supporting future translational development of rho-associated kinase inhibitors in ischemic stroke.
引用
- Imai T, Morais AL, Jin X, et al. Multicenter SPAN Trial of Fasudil in Ischemic Stroke. Stroke. 2025. PMID: 40421536. doi:10.1161/STROKEAHA.125.050977
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。